Slide 1: Q2 2025 Earnings Call Presentation
Q2 2025 Earnings Call Presentation August │ 2025 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Auna S.A. (“Auna” or the “Company”) solely for use at this presentation. This presentation is confidential to the recipient. Accordingly, any attempt to copy, summarize or distribute this presentation or any portion hereof in any form to any other pa
Slide 3: Today's Speakers
Today’s Speakers +30 +20 +25 Jesus Zamora Gisele Remy Lorenzo Massart Executive Chairman of the Board and Chief Financial Officer and Executive Vice President, Strategy and President Executive Vice President Equity Capital Markets • Member of the Board since 2008 and President • Chief Financial Offi
Slide 4: 2Q 2025 Highlights
2Q 2025 Highlights Adjusted EBITDA1 -3% YoY or +5% FXN2, with flat margin at 21.1% YoY Reported results impacted by depreciation of PEN/MXN (-16%) and PEN/COP (-9%) YoY “Each segment Continuous delivery in Peru resulting from strategic medical retention in the network driving surgery conversion and
Slide 5: Consolidated 2Q25 revenue and Adjusted EBITDA
Adjusted EBITDA increases 5% FXN YoY; with all segments positively contributing to results in local currency Consolidated 2Q25 Revenue (S/) Adjusted EBITDA(1) (S/) 1,094 Mn 241 Mn -2% YoY -3% YoY +4% FXN YoY +5% FXN YoY Healthcare Services Oncosalud Peru Total Capacity Plan Oncology Oncology Bed Uti
Slide 6: Q2 2025 Results by Segment
Q2 2025 Results by Segment qauna
Slide 7: Healthcare Services Mexico growth supported by higher average ticket and pricing mix
Healthcare Services Mexico growth supported by higher average ticket and pricing mix in non-core service lines External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 27% of LTM Revenues 41% of LTM Adj. EBITDA 33.1% 33.2% 32.0% 33.4% 32.6% +1% (L.C) +2% (L.C) -12% -2% (L.C) +5% (L.C) -15%
Slide 8: Peruvian healthcare and Oncosalud segments outperform
Peruvian healthcare and Oncosalud segments outperform, supported by plan membership growth and improved MLRs External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 40% of LTM Revenues 38% of LTM Adj. EBITDA 21.2% 22.1% 21.3% 20.8% 21.7% +8% +3% +9% 474 +8% +13% 460 934 441 859 -1% 203 102
Slide 9: Colombia's improved results supported by risk-sharing models and payor diversification
Colombia´s improved results supported by risk-sharing models, payor mix diversification and improved collections cycle from NEPS External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 33% of LTM Revenues 22% of LTM Adj. EBITDA 15.3% 16.7% 12.2% 14.8% 14.5% +0% (L.C) +3% (L.C) +9% (L.C) -8
Slide 10: Q2 2025 Consolidated Results
Q2 2025 Consolidated Results 10
Slide 11: Oncosalud, HC Peru and HC Mexico improved revenues
Oncosalud, HC Peru and HC Mexico improved revenues, while Colombia maintained its revenue levels as planned under this segment´s strategy ▪ 2Q25 YoY revenues increased 8% in Peru and remained flat in Colombia, while Mexico increased 5% in L.C. ▪ Peru HC services grew on increased surgeries, while On
Slide 12: Adjusted EBITDA -3% or +5% FXN YoY
Adjusted EBITDA1 -3% or +5% FXN YoY, impacted by expenses related to medical talent retention in Mexico and Peru and sales commissions at Oncosalud ▪ Adjusted EBITDA Margin1 flat YoY at 22.1% in 2Q25 ▪ PEN/MXN decline of 16% and PEN/COP decline of 9% YoY ▪ In Peru, Adjusted EBITDA1 delivered 6% YoY
Slide 13: Adjusted Net Income increased +6x YoY
Adjusted Net Income1 increased +6x YoY ▪ Sixth consecutive quarter of positive Adjusted Net Income Adjusted Net Income1 bridge: 2Q’24 vs 2Q’25 (S/ Mn) 18 53 89 0 118 Adjusted 13 Adjusted EPS2 : 6 EPS2 : S/ 0.12 S/ 1.17 Adj. Net Operating Profit Fx variance Net interest Income tax Non-cash and Adj. N
Slide 14: End of period cash remains at healthy levels
End of period cash remains at healthy levels, although it continued to be impacted by collections in Q1 2025 and payments to Opción Oncología doctors ▪ Pre-tax operating cash flow grew versus 1Q 2025 ▪ Free cash flow includes S/19 million in payments to Opción Oncología doctors ▪ Interest reflects s
Slide 15: Maintained healthy debt structure and leverage ratio while improving maturity profile
Maintained healthy debt structure and leverage ratio while improving maturity profile Debt Structure Highlights Debt by Type (%) Debt by Currency (%) ✓ Intend to further reduce leverage since the 2022 acquisitions of Consolidated Debt: S/ 3,702 Monterrey, Mexico network and IMAT Oncomedica in Colomb
Slide 16: Management closing remarks on remainder of 2025
We remain committed to advancing and transforming healthcare in SSLA “During the through Auna’s value-based care model, to enhance medical resolutions while optimizing our platform, and driving sustainable and profitable growth. remainder of While each segment is at a different maturity stage, each
Slide 17: Q&A
Q&A quna
Slide 18: Exhibits
Exhibits qund
Slide 19: Consolidated Balance Sheet
Consolidated Balance Sheet (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Jun-25 Δ Jun-25 Jun-25 Δ Jun-25 Jun-25 Dec-24 Jun-25 Dec-24 (USD) vs Dec-24 (USD) vs Dec-24 Assets Liabilities Current assets Current liabilities Cash and cash equivalents 49 175 236 (61)
Slide 20: Consolidated Statement of Income (1/2)
Consolidated Statement of Income (1/2) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) 2Q'25 Δ 2Q'25 vs Δ YTD 25 vs 2Q'25 YTD 25 (USD) 2Q'24 1Q'25 YTD 24 Revenue Healthcare Services Mexico 77 274 517 -9% 13% -15% Healthcare Services Colombia 98 346 685 -8% 2% -6
Slide 21: Consolidated Statement of Income (2/2)
Consolidated Statement of Income (2/2) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) 2Q'25 Δ 2Q'25 vs Δ YTD 25 vs 2Q'25 YTD 25 (USD) 2Q'24 1Q'25 YTD 24 Share of profit of equity accounted investees 1 2 5 5% -13% 15% Profit (loss) before tax 37 132 194 20.4x 11
Slide 22: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) YTD 25 Δ YTD 25 vs YTD 25 Δ YTD 25 vs YTD 25 YTD 24 YTD 25 YTD 24 (USD) YTD 24 (USD) YTD 24 Cash flows from operating activities Cash flows from investing activities (Loss) profit f
Slide 23: Adjusted EBITDA and Adjusted EBITDA Margin reconciliation
Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted EBITDA: is calculated as profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre- operating expenses for
Slide 24: Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued)
Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) At the segment level, 2Q25 adjustments include (i) Pre-operating expenses of S/0.5 million in Holdings and eliminations, (ii) Business developme
Slide 25: Consolidated Peru Adjusted EBITDA and Adjusted EBITDA Margin reconciliation
Consolidated Peru Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Consolidated Peru Adjusted EBITDA: is calculated by adding Healthcare Services Peru Segment Adjusted EBITDA plus Oncosalud Peru Segment Ad
Slide 26: Adjusted Net Income reconciliation
Adjusted Net Income reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted Net Income: is calculated as profit (loss) for the period plus adjustments as described below. 2Q'25 2Q'25 2Q'24 YTD 25 YTD 24 (USD) Net Income (Loss) 24 84 8 122 (0) (a)
Slide 27: Free Cash Flow
Free Cash Flow (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Free Cash Flow: is calculated by adding Net Cash Flows from Operations and Net Cash Flows used in Investment activities. Jun-25 Cash from Operating Activities 346,044 (-) Income t ax 103,758 (+) Int
Slide 28: Adjusted Basic and Diluted Earnings per Share
Adjusted Basic and Diluted Earnings per Share (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted Basic and Diluted Earnings per Share: Adjusted Basic and Diluted Earnings per Share is calculated by dividing profit attributable to owners of Adjusted Net Inc
Slide 29: Net Debt reconciliation
Net Debt reconciliation (Figures in millions of Soles, unless expressed otherwise) Net Debt: We calculate Net Debt as Gross Debt minus Cash and cash equivalents. 2021 2022 2023 4Q'24 2Q'25 (+) Loans and borrowings 1,352 3,349 3,762 3,620 3,574 Short t erm debt 30 2,041 385 654 598 Long t erm debt 1,
Slide 30: Leverage Ratio reconciliation
Leverage Ratio reconciliation (Figures in millions of Soles, unless expressed otherwise) Leverage Ratio: is calculated as (i) current and non-current loans and borrowings plus current and non-current lease liabilities minus (ii) cash and cash equivalents, divided by (iii) Last twelve months Adjusted
Slide 31: Key Operational Metrics – Oncosalud Peru & Healthcare Services
Key Operational Metrics – Oncosalud Peru & Healthcare Services 1) As of period end and as reported to the National Superintendence of Health Susalud. Includes Oncology plans and Health plans. Δ 2Q'25 vs 2) Includes active plan members and inactive members. Inactive members are defined as 2Q'25 2Q'24
Slide 32: Trends in Key Financial Metrics
Trends in Key Financial Metrics (Figures in millions of Soles, unless expressed otherwise) 2Q'23 3Q'23 4Q'23 1Q'24 2Q'24 3Q'24 4Q'24 1Q'25 2Q'25 Revenue Oncosalud Peru 230 237 244 253 269 273 276 281 286 Healthcare Services Peru 217 230 225 241 255 255 245 263 269 Healthcare Services Colombia 282 32
Slide 33: Investor Relations
Investor Relations contact@aunainvestors.com www.aunainvestors.com 33